Print this page
George
-
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease.
Protocol: 042604Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
SHORTened duration of TAMoxifen for risk reduction in breast intraepithelial neoplasms in post-menopausal women.
Protocol: 042606Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease.
Protocol: 042604Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
SHORTened duration of TAMoxifen for risk reduction in breast intraepithelial neoplasms in post-menopausal women.
Protocol: 042606Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
Tracking Health and Resilience in Metastatic Colorectal Cancer: THRIVE-MCRC
Protocol: 132314Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
Tracking Health and Resilience in Metastatic Colorectal Cancer: THRIVE-MCRC
Protocol: 132314Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon -
Clinician Attributes for Treatment Relinquishment at the End of Life (CARE)
Protocol: 132516Principal Investigator:
- Login George
Applicable Disease Sites: Any Site -
Coping and Decision-Making in Cancer II
Protocol: 132608Principal Investigator:
- Login George
Applicable Disease Sites: Any Site -
Clinician Attributes for Treatment Relinquishment at the End of Life (CARE)
Protocol: 132516Principal Investigator:
- Login George
Applicable Disease Sites: Any Site -
Coping and Decision-Making in Cancer II
Protocol: 132608Principal Investigator:
- Login George
Applicable Disease Sites: Any Site